Keith C Bible1, Electron Kebebew2, James Brierley3, Juan P Brito4, Maria E Cabanillas5, Thomas J Clark6, Antonio Di Cristofano7, Robert Foote8, Thomas Giordano9, Jan Kasperbauer10, Kate Newbold11, Yuri E Nikiforov12, Gregory Randolph13, M Sara Rosenthal14, Anna M Sawka15, Manisha Shah16, Ashok Shaha17, Robert Smallridge18, Carol K Wong-Clark. 1. Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA. 2. Stanford University, School of Medicine, Stanford, California, USA. 3. Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada. 4. Division of Diabetes, Endocrinology, Metabolism, and Nutrition, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. 5. Department of Endocrine Neoplasia & Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 6. Thermo Fisher Scientific, Carlsbad, California, USA. 7. Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, New York, USA. 8. Department of Radiation Oncology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA. 9. Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA. 10. Department of Otolaryngology, Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota, USA. 11. The Royal Marsden NHS Foundation Trust, Fulham Road, London, United Kingdom. 12. Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 13. Division of Thyroid and Parathyroid Endocrine Surgery, Massachusetts Eye and Ear, Boston, Massachusetts, USA. 14. Program for Bioethics and Markey Cancer Center Oncology Ethics Program, Departments Internal Medicine, Pediatrics and Behavioral Science, University of Kentucky, Lexington, Kentucky, USA. 15. Division of Endocrinology, Department of Medicine, University Health Network and University of Toronto, Toronto, Canada. 16. The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA. 17. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 18. Mayo Clinic, Jacksonville, Florida, USA.
Abstract
Background: Anaplastic thyroid cancer (ATC) is a rare but highly lethal form of thyroid cancer. Since the guidelines for the management of ATC by the American Thyroid Association were first published in 2012, significant clinical and scientific advances have occurred in the field. The aim of these guidelines is to inform clinicians, patients, and researchers on published evidence relating to the diagnosis and management of ATC. Methods: The specific clinical questions and topics addressed in these guidelines were based on prior versions of the guidelines, stakeholder input, and input of the Task Force members (authors of the guideline). Relevant literature was reviewed, including serial PubMed searches supplemented with additional articles. The American College of Physicians Guideline Grading System was used for critical appraisal of evidence and grading strength of recommendations. Results: The guidelines include the diagnosis, initial evaluation, establishment of treatment goals, approaches to locoregional disease (surgery, radiotherapy, targeted/systemic therapy, supportive care during active therapy), approaches to advanced/metastatic disease, palliative care options, surveillance and long-term monitoring, and ethical issues, including end of life. The guidelines include 31 recommendations and 16 good practice statements. Conclusions: We have developed evidence-based recommendations to inform clinical decision-making in the management of ATC. While all care must be individualized, such recommendations provide, in our opinion, optimal care paradigms for patients with ATC.
Background: Anaplastic thyroid cancer (ATC) is a rare but highly lethal form of thyroid cancer. Since the guidelines for the management of ATC by the American Thyroid Association were first published in 2012, significant clinical and scientific advances have occurred in the field. The aim of these guidelines is to inform clinicians, patients, and researchers on published evidence relating to the diagnosis and management of ATC. Methods: The specific clinical questions and topics addressed in these guidelines were based on prior versions of the guidelines, stakeholder input, and input of the Task Force members (authors of the guideline). Relevant literature was reviewed, including serial PubMed searches supplemented with additional articles. The American College of Physicians Guideline Grading System was used for critical appraisal of evidence and grading strength of recommendations. Results: The guidelines include the diagnosis, initial evaluation, establishment of treatment goals, approaches to locoregional disease (surgery, radiotherapy, targeted/systemic therapy, supportive care during active therapy), approaches to advanced/metastatic disease, palliative care options, surveillance and long-term monitoring, and ethical issues, including end of life. The guidelines include 31 recommendations and 16 good practice statements. Conclusions: We have developed evidence-based recommendations to inform clinical decision-making in the management of ATC. While all care must be individualized, such recommendations provide, in our opinion, optimal care paradigms for patients with ATC.
Entities:
Keywords:
BRAF; IMRT (intensity-modulated radiotherapy); SBRT (stereotactic body radiation therapy); chemoradiation; chemotherapy; ethics; multimodality therapy; palliative care; radiation therapy; squamous cell cancer of the thyroid; surgery; targeted therapy; undifferentiated thyroid cancer
Authors: Nathan A Pennell; Gilbert H Daniels; Robert I Haddad; Douglas S Ross; Tracey Evans; Lori J Wirth; Panos H Fidias; Jennifer S Temel; Sarada Gurubhagavatula; Rebecca Suk Heist; John R Clark; Thomas J Lynch Journal: Thyroid Date: 2008-03 Impact factor: 6.568
Authors: Henry G Yu; Krikor Bijian; Sabrina D da Silva; Jie Su; Gregoire Morand; Alan Spatz; Moulay A Alaoui-Jamali Journal: Oncogene Date: 2022-04-22 Impact factor: 9.867
Authors: Tam N M Ngo; Trang T B Le; Thoa Le; Andrey Bychkov; Naoki Oishi; Chan Kwon Jung; Lewis Hassell; Kennichi Kakudo; Huy Gia Vuong Journal: Endocr Pathol Date: 2021-09-24 Impact factor: 3.943
Authors: Marcio José Concepción Zavaleta; Sofia Pilar Ildefonso Najarro; Esteban Alberto Plasencia Dueñas; María Alejandra Quispe Flores; Diego Martín Moreno Marreros; Luis Alberto Concepción Urteaga; Laura Esther Luna Victorio; Freddy Valdivia Fernández Dávila Journal: Endocrinol Diabetes Metab Case Rep Date: 2021-07-01
Authors: Antonio Matrone; Luigi De Napoli; Liborio Torregrossa; Aleksandr Aghababyan; Piermarco Papini; Carlo Enrico Ambrosini; Rosa Cervelli; Clara Ugolini; Fulvio Basolo; Eleonora Molinaro; Rossella Elisei; Gabriele Materazzi Journal: Front Oncol Date: 2022-04-05 Impact factor: 5.738